Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Torisel’s Positive Effect on Overall Survival Expected To Drive Sales

Executive Summary

Wyeth is projecting that Torisel will capture a 25 percent share of the global renal cell carcinoma market within three years following its July launch

You may also be interested in...



Novartis Speeds RAD001 Filing Schedule After Presenting RECORD-1 At ASCO

CHICAGO - With data in hand showing RAD001 (everolimus) doubled progression-free survival in metastatic kidney cancer, Novartis is accelerating its submission schedule and plans to file for the indication by July for a possible 2009 launch of its mTOR inhibitor for oncology

Novartis Speeds RAD001 Filing Schedule After Presenting RECORD-1 At ASCO

CHICAGO - With data in hand showing RAD001 (everolimus) doubled progression-free survival in metastatic kidney cancer, Novartis is accelerating its submission schedule and plans to file for the indication by July for a possible 2009 launch of its mTOR inhibitor for oncology

Lybrel, Torisel launches underway

Wyeth is shipping its May approvals in earnest beginning this month, firm says during a July 19 earnings call. Launches of continuous oral contraceptive Lybrel (levonorgestrel/ethinyl estradiol) and renal cell carcinoma treatment Torisel (temsirolimus) are the first of seven launches planned for the next 18 months, Chief Operating Officer Bernard Poussot says. Promotional materials are being finalized and active promotion will begin shortly, Poussot adds (1"The Pink Sheet" June 4, 2007, p. 3)...

Related Content

UsernamePublicRestriction

Register

PS048436

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel